Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

10/06/2015 The Barcelona Synchrotron Park in the SmartReFlex European project 01/06/2015 SENER and ALBA sign a technology transfer agreement 28/05/2015 Synchrotron light applications for the pharmaceutical industry 20/05/2015 Financial Times ranks ESADE 7th worldwide in open executive education programmes 14/05/2015 Joint promotion in Korea of the Barcelona Synchrotron Park and the Parc Científic de Barcelona 07/05/2015 The UAB ranks well
32 33 34 35 36 37 38 39 40 41 42